[Clinical study of a new local blocking agent with a polypeptide vasoconstrictor (Citanest-Octapresin) in patients with cardiovascular and other changes].
D000083:Acetanilides / Q000494:pharmacology*; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000779:Anesthetics, Local; D001161:Arteriosclerosis; D002986:Clinical Trials as Topic; D003327:Coronary Disease; D005259:Felypressin / Q000494:pharmacology; D005260:Female; D006333:Heart Failure; D006801:Humans; D006973:Hypertension; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D010455:Peptides; D011422:Propionates / Q000494:pharmacology*; D011437:Propylamines / Q000494:pharmacology*; D014050:Toluene / Q000494:pharmacology*; D014081:Tooth Extraction; D014667:Vasopressins / Q000494:pharmacology*
D000083:Acetanilides; D000779:Anesthetics, Local; D010455:Peptides; D011422:Propionates; D011437:Propylamines; D014667:Vasopressins; D014050:Toluene; D005259:Felypressin
Estudio clínico de un nuevo bloqueador local con un polipeptido vasoconstructor (citanestoctapresin) en pacientes con alteraciones cardiovasculares y otros.